Pregnancy is a time of joy, but it can also be a period of hidden health risks, one of which is iron deficiency—a condition far more common than most realize. Did you know that two-thirds of pregnant women screened in a recent study were found to be iron deficient? This startling fact highlights a widespread yet often overlooked issue. But here’s where it gets even more eye-opening: a groundbreaking quality improvement project at the Mayo Clinic has not only shed light on this problem but has also dramatically transformed how it’s addressed. Within just one year, the project achieved a sixfold increase in iron deficiency screening rates among pregnant patients, a staggering 20-fold rise in intravenous (IV) iron infusions, and a significant boost in median hemoglobin levels. Screening rates soared from a mere 10% to over 60%, revealing that iron deficiency is not only prevalent but also highly treatable.
Led by Dr. Richard Godby, a hematologist at the Mayo Clinic in Rochester, Minnesota, this multidisciplinary initiative tackled the issue head-on. Dr. Godby explains that women of childbearing age are particularly vulnerable to iron deficiency due to factors like menstruation, inadequate intake of iron-rich foods, and even common medications like proton pump inhibitors, which can hinder iron absorption. During pregnancy, the body’s iron needs skyrocket, and untreated deficiency can lead to serious complications, including fetal growth restriction, premature birth, low birth weight, and impaired brain and nervous system development in the fetus. Yet, current guidelines from the American College of Obstetricians and Gynecologists recommend screening only for pregnant women with anemia—defined as a hemoglobin level below 11 g/dL in the first or third trimester. Is this threshold too narrow? Could we be missing opportunities to protect both mothers and babies?
The Mayo Clinic team standardized screening and treatment by adding ferritin testing—a blood test that measures iron stores—to routine lab work at 8-12 weeks and 24-28 weeks of pregnancy. If ferritin levels were low, patients were offered oral iron supplements early on or IV iron infusions later in pregnancy. The results were striking: in the year following implementation, 63% of patients were screened for iron deficiency, compared to just 10% before. Among those tested, nearly 70% were found to be deficient, and 21% received IV iron infusions, up from a mere 0.9% previously. Hemoglobin levels improved significantly, with some patients seeing increases from 10.7 g/dL to 11.8 g/dL. Even those with initial levels above the anemia threshold (12 g/dL) saw improvements, rising to 12.8 g/dL. Should we reconsider what constitutes 'normal' hemoglobin levels during pregnancy?
Another intriguing finding: the need for blood transfusions during delivery decreased slightly after the project, though not statistically significant. Most patients requiring transfusions had not been tested for iron deficiency, suggesting that early intervention could reduce postpartum complications. Dr. Godby also points out that while nearly all patients took prenatal vitamins, many were over-the-counter supplements, which are not regulated for ingredient accuracy. Are we relying too heavily on unregulated supplements to meet critical nutritional needs?
Looking ahead, the team plans to explore whether treating iron deficiency during pregnancy improves quality of life, reducing postpartum depression and helping mothers return to work sooner. Dr. Godby will present these findings on December 7, 2025, at the Orange County Convention Center, inviting further discussion on this vital topic. And this is the part most people miss: iron deficiency in pregnancy isn’t just a minor issue—it’s a preventable problem with far-reaching consequences. What do you think? Should screening guidelines be expanded, or is the current approach sufficient? Share your thoughts in the comments—let’s spark a conversation that could change how we care for pregnant women and their babies.
